PDCD1 and cancer: On the other hand, cancer and antigen-presenting cells in the tumor microenvironment (TME) produce PD-1 ligands including PD-L-1 (B7-H1) and PD-L-2 (B7-DC), which, impair anticancer immunity when bind to the PD-1 receptor (5–7).